〔Abstract〕 Objective To investigate the effects of ursodeoxycholic acid on liver function and pregnancy outcomes in patients with intrahepatic cholestasis syndrome during pregnancy. Methods A total of 138 patients with intrahepatic cholestasis syndrome of pregnancy admitted to Joint Support Force 989th Hospital from February 2018 to November 2019 were selected and randomly divided into a control group and an observation group, with 69 cases in each group. The control group received conventional drug treatment, and the observation group received ursodeoxycholic acid combined with conventional drug treatment. The changes in liver function indexes and pregnancy outcomes were compared between the two groups. Results After treatment, the levels of liver function indicators such as aspartate transaminase (AST), total bile acid (TBA), total bilirubin (TBIL) and alanine transaminase (ALT) in the two groups were lower than those before treatment, and the observation group were lower than those in the control group, with a statistically significant difference (P < 0.05); The incidence of cesarean section, postpartum hemorrhage, neonatal asphyxia or distress, and amniotic fluid contamination in the observation group was lower than that in the control group, and the difference was statistically significant (P < 0.05); The gestational circumference of the observation group patients at the time of termination of pregnancy was longer than that of the control group, while the neonatal body mass of the observation group patients at the time of termination of pregnancy was heavier than that of the control group, with a statistically significant difference (P < 0.05). Conclusion Ursodeoxycholic acid has a good effect on improving liver function in patients with intrahepatic cholestasis syndrome during pregnancy, and the combined medication has better pregnancy outcomes than conventional treatment regimens.